Video: An overview of the monkeypox virus

Video: An overview of the monkeypox virus

Kalpana Pot walks us through the latest information on the monkeypox outbreak.

Leaps.org

Click below for an overview of everything you need to know about the latest status of monkeypox - in 58 seconds.



An Overview of Monkeypox with Kalpana Pot

An Overview of the Monkeypox Virus youtube.com

Kalpana Pot
Kalpana Pot is the youngest of three girls in a family full of doctors. Science and education were always of great value in her home. But performing arts was another passion for her, which is why she moved to LA to pursue acting after decades of dancing and singing. She’s appeared on numerous TV shows and national commercials, and will soon be co-hosting Wheel of Fortune Live. At the same time, Kalpana got to express her nerd love of astronomy by working weekends at Griffith Observatory. It was there that she found her love and skill in communicating science to people from all over the world, and has since continued to host space/science series. She has translated that onto digital platforms as well- running an outspoken space-page on TikTok, called TokNerdyToMe, and style and science page on Instagram. Unfortunately, much of her science communication these days is about debunking anti-science conspiracies. But she’s confident that the rise of educational content on social media will help this unfortunate problem in society. Outside of work, Kalpana loves her dogs and volunteers for animal organizations.
Heart model

Elaine Kamil had just returned home after a few days of business meetings in 2013 when she started having chest pains. At first Kamil, then 66, wasn't worried—she had had some chest pain before and recently went to a cardiologist to do a stress test, which was normal.

"I can't be having a heart attack because I just got checked," she thought, attributing the discomfort to stress and high demands of her job. A pediatric nephrologist at Cedars-Sinai Hospital in Los Angeles, she takes care of critically ill children who are on dialysis or are kidney transplant patients. Supporting families through difficult times and answering calls at odd hours is part of her daily routine, and often leaves her exhausted.

Keep Reading Keep Reading
Lina Zeldovich

Lina Zeldovich has written about science, medicine and technology for Popular Science, Smithsonian, National Geographic, Scientific American, Reader’s Digest, the New York Times and other major national and international publications. A Columbia J-School alumna, she has won several awards for her stories, including the ASJA Crisis Coverage Award for Covid reporting, and has been a contributing editor at Nautilus Magazine. In 2021, Zeldovich released her first book, The Other Dark Matter, published by the University of Chicago Press, about the science and business of turning waste into wealth and health. You can find her on http://linazeldovich.com/ and @linazeldovich.

Did Anton the AI find a new treatment for a deadly cancer?

Researchers used a supercomputer to learn about the subtle movement of a cancer-causing molecule, and then they found the precise drug that can recognize that motion.

Matthew Monteith

Bile duct cancer is a rare and aggressive form of cancer that is often difficult to diagnose. Patients with advanced forms of the disease have an average life expectancy of less than two years.

Many patients who get cancer in their bile ducts – the tubes that carry digestive fluid from the liver to the small intestine – have mutations in the protein FGFR2, which leads cells to grow uncontrollably. One treatment option is chemotherapy, but it’s toxic to both cancer cells and healthy cells, failing to distinguish between the two. Increasingly, cancer researchers are focusing on biomarker directed therapy, or making drugs that target a particular molecule that causes the disease – FGFR2, in the case of bile duct cancer.

A problem is that in targeting FGFR2, these drugs inadvertently inhibit the FGFR1 protein, which looks almost identical. This causes elevated phosphate levels, which is a sign of kidney damage, so doses are often limited to prevent complications.

In recent years, though, a company called Relay has taken a unique approach to picking out FGFR2, using a powerful supercomputer to simulate how proteins move and change shape. The team, leveraging this AI capability, discovered that FGFR2 and FGFR1 move differently, which enabled them to create a more precise drug.

Keep Reading Keep Reading
Sarah Philip
Sarah Philip is a London-based freelance journalist who writes about science, film and TV. You can follow her on Twitter @sarahph1lip.